Thousands of National Health Service (NHS) patients in England with persistent acid reflux could avoid invasive hospital endoscopy procedures after health officials recommended a seven-minute sponge test to detect changes linked to oesophageal cancer.

The National Institute for Health and Care Excellence (NICE) published draft guidance on Monday, 16 November, recommending Cytosponge and EndoSign for certain higher-risk patients.

The tests could also offer another way to monitor people already diagnosed with Barrett's oesophagus, a condition associated with increased cancer risk. Wider use of the test could reduce pressure on hospital endoscopy services, although final approval is still pending.

Patients With Acid Reflux Could Be Tested Closer to Home

The proposed service is aimed at people with persistent gastro-oesophageal reflux disease and additional risk factors who do not require an urgent suspected-cancer referral. Checks could take place in GP surgeries, pharmacies or community diagnostic centres, rather than requiring a hospital visit.

The tests have already been used in NHS pilots, which NHS England says have benefited thousands of patients.

During the procedure, patients swallow a small capsule attached to a thread. The capsule then dissolves in the stomach, releasing a sponge that is withdrawn through the mouth to collect cells from the oesophagus. The sample is then analysed for abnormal changes, and the procedure does not require sedation.

Barrett's Oesophagus Raises Cancer Risk

Barrett's oesophagus develops when cells lining the lower food pipe change, often after long-term acid reflux. NICE estimates it affects 1% to 2% of adults, although most people with the condition never develop cancer.

Reflux can cause recurring heartburn or a sour taste, while Barrett's itself may not produce symptoms.

About 9,500 people are diagnosed with oesophageal cancer in the UK each year, according to Cancer Research UK. The charity says only about 19% of cases with a recorded stage in England were found at stages one or two in 2022.

Around 75% of patients diagnosed at stage one survive at least five years, compared with 6% at stage four. NHS warning signs include difficulty swallowing, unexplained weight loss and persistent or worsening indigestion, which should be assessed by a GP.

Abnormal Results Still Require Endoscopy

The sponge procedure would not replace endoscopy for patients whose results suggest cancer or Barrett's oesophagus. Those patients would still need further examination with a camera passed down the throat, and biopsies where necessary.

A negative sponge result also cannot rule out all disease, so ongoing monitoring and medical advice remain important.

NICE's committee said patients generally preferred capsule testing because it was quicker and less intrusive. The procedure can cause brief discomfort or a sore throat, but serious complications are uncommon.

Compared with endoscopy, it requires fewer clinical staff and could reserve hospital appointments for patients needing more detailed investigations.

The consultation on the proposed recommendations closes on 7 December, with final NICE guidance expected in February 2027.

If approved, the tests would be introduced more consistently for eligible patients across England under the National HealthTech Access Programme. The NHS would still need to arrange staff training and local services before expanding access.